A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus

(2014) Zev Sthoeger et al.   JOURNAL OF AUTOIMMUNITY

Systemic lupus erythematosus: an update on current pharmacotherapy and future directions

(2013) Zahi Touma et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys

(2013) Aikaterini Thanou et al.   Nature Reviews Rheumatology

Activation of the Interferon Pathway is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients

(2013) Kichul Ko et al.   Frontiers in Immunology

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study

(2012) Jacqueline M. McBride et al.   ARTHRITIS AND RHEUMATISM

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus

(2012) M Postal et al.   Clinics

Optimization of current and future therapy for autoimmune diseases

(2012) Lawrence Steinman et al.   NATURE MEDICINE

The genetics of systemic lupus erythematosus and implications for targeted therapy

(2011) A. L. Sestak et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment

(2011) K.M.A.C. Luijten et al.   AUTOIMMUNITY REVIEWS

Type I Interferon and Systemic Lupus Erythematosus

(2011) Keith B. Elkon et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Systemic Lupus Erythematosus

(2011) George C. Tsokos   NEW ENGLAND JOURNAL OF MEDICINE

The type I interferon system in the etiopathogenesis of autoimmune diseases

(2011) Lars Rönnblom   UPSALA JOURNAL OF MEDICAL SCIENCES

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort

(2011) M. B. Urowitz et al.   ARTHRITIS CARE & RESEARCH

Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus

(2010) Corinna E. Weckerle et al.   ARTHRITIS AND RHEUMATISM

A novel homogeneous Biotin–digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum

(2010) Zhihua Julia Qiu et al.   JOURNAL OF IMMUNOLOGICAL METHODS

What can we learn from genetic studies of systemic lupus erythematosus? Implications of genetic heterogeneity among populations in SLE

(2010) H-S. Lee et al.   LUPUS

Numerical scoring for the BILAG-2004 index

(2010) Chee-Seng Yee et al.   RHEUMATOLOGY

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM

Recent insights into the genetic basis of systemic lupus erythematosus

(2009) K L Moser et al.   GENES AND IMMUNITY

Accumulation of coronary artery disease risk factors over three years: Data from an international inception cohort

(2008) M. B. Urowitz et al.   ARTHRITIS AND RHEUMATISM